Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial.
BACKGROUND Trypanosoma cruzi infection affects over seven million people worldwide. Standard-of-care benznidazole or nifurtimox causes drug-related adverse events leading to definitive treatment interruption. We evaluated whether shortened, extended, or halved-dose regimens preserve efficacy and improve tolerability....